Page 2419 - Williams Hematology ( PDFDrive )

2390 Part XIII: Transfusion Medicine Chapter 139: Preservation and Clinical Use of Platelets 2391

REFERENCES 33. Harker LA, Malpass TW, Branson HE, et al: Mechanism of abnormal bleeding in
patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction
1. Report of the US Department of Health and Human Services: The 2009 National Blood associated with selective alpha-granule release. Blood 56:824, 1980.
Collection and Utilization Survey Report. US Department of Health and Human Ser- 34. Cooper ES, Bracey AW, Horvath AE, et al: Practice parameter for the use of fresh-
vices, Office of the Assistant Secretary for Health, Washington, DC, 2011. frozen plasma, cryoprecipitate, and platelets. JAMA 271:777, 1994.
2. Slichter SJ, Harker LA: Thrombocytopenia: Mechanisms and management of defects in 35. Perkins JG, Cap PA, Spinella PC, et al: An evaluation of the impact of apheresis platelets
platelet production. Clin Haematol 7:523, 1978. used in the setting of massively transfused trauma patients. J Trauma 66:S77, 2009.
3. Hanson SR, Slichter SJ: Platelet kinetics in patients with bone marrow hypoplasia: Evi- 36. Simmons JW, White CE, Eastridge BJ, et al: Impact of policy change on US Army com-
dence for a fixed platelet requirement. Blood 66:1105. 1985. bat transfusion practices. J Trauma 69 Suppl 1:S75, 2010.
4. Gaydos LA, Freireich EJ, Mantel N: The quantitative relation between platelet count and 37. Baraniuk S, Tilley BC, del Junco DJ, et al: Pragmatic Randomized Optimal Platelet and
hemorrhage in patients with acute leukemia. N Engl J Med 266:905, 1962. Plasma Ratios (PROPPR) Trial: Design, rationale and implementation. Injury 45:1287,
5. Gmür J, Burger J, Schanz U, et al: Safety of stringent prophylactic platelet transfusion 2014.
policy for patients with acute leukaemia. Lancet 338:1223, 1991. 38. Holcomb JB, Tilley BC, Baraniuk S, et al for the PROPPR Study Group: Transfusion of
6. Slichter SJ, Kaufman RM, Assman SF, et al: Dose of prophylactic platelet transfusions plasma, platelets, and red blood cells in a 1:1:1 vs. a 1:1:2 ratio and mortality in patients
and prevention of hemorrhage. N Engl J Med 362:600, 2010. with severe trauma: The PROPPR Randomized Clinical Trial. JAMA 313:483, 2015.
7. Harker LA, Slichter SJ: The bleeding time as a screening test for evaluation of platelet 39. Kocsis JJ, Hernandovich J, Silver MJ, et al: Duration of inhibition of platelet prostaglan-
function. N Engl J Med 287:155, 1972. din formation and aggregation by ingested aspirin or indomethacin. Prostaglandins
8. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. 3:141, 1973.
Cancer 47:207, 1981. 40. Davis KB, Slichter SJ, Corash L: Corrected count increment and percent platelet
9. Stanworth SJ, Estcourt L, Powter G, et al: A no-prophylaxis platelet-transfusion strategy recovery as measures of posttransfusion platelet response: Problems and a solution.
for hematologic cancers. N Engl J Med 368:1771, 2013. Transfusion 39: 586, 1999.
10. Josephson CD, Granger S, Assmann SF, et al: Bleeding risks are higher in children ver- 41. Doughty HA, Murphy MF, Metcalfe P, et al: Relative importance of immune and
sus adults given prophylactic platelet transfusions for treatment-induced hypoprolifer- non-immune causes of platelet refractoriness. Vox Sang 66: 200, 1994.
ative thrombocytopenia. Blood 120:748, 2012. 42. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmuniza-
11. American Cancer Society: Cancer Facts & Figures 2012. American Cancer Society, tion and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization
Atlanta, GA, 2012. To Platelets Study Group. N Engl J Med 337:1861, 1997.
12. Palomo M, Diaz-Ricart M, Carbo C, et al: Endothelial dysfunction after hematopoietic 43. Heal JM, Blumberg N, Masel D: An evaluation of crossmatching, HLA, and ABO
stem cell transplantation: Role of the conditioning regimen and the type of transplanta- matching for platelet transfusions to refractory patients. Blood 70:23,1987.
tion. Biol Blood Marrow Transplant 16:985, 2010. 44. Bishop JF, McGrath K, Wolf MM, et al: Clinical factors influencing the efficacy of
13. Goerge T, Ho-Tin-Noe B, Carbo C, et al: Inflammation induces hemorrhage in throm- pooled platelet transfusions. Blood 71:383. 1988.
bocytopenia. Blood 111:4958, 2008. 45. Klumpp TR, Herman JH, Innis S, et al: Bone Marrow Transplant 17:1035, 1996.
14. Han T, Stutzman L, Cohen E, Kim U: Effect of platelet transfusion on hemorrhage in 46. Salama A, Kiesewetter, Kalus U, et al: Massive platelet transfusion is a rapidly effec-
patients with acute leukemia. An autopsy study. Cancer 19:1937, 1966. tive emergency treatment in patients with refractory autoimmune thrombocytopenia.
15. Hanson SR, Slichter SJ: Platelet kinetics in patients with bone marrow hypoplasia: Evi- Thromb Haemost 100:762, 2008.
dence for a fixed platelet requirement. Blood 66:1105, 1985. 47. Peña JR, Saidman SL: Anti-HLA antibody testing in hematology patients. Am J Hematol
16. Rebulla P, Finazzi G, Marangoni F, et al:: The threshold for prophylactic platelet trans- 90:361, 2015.
fusions in adults with acute myeloid leukemia. Gruppo Italiano Malatie Ematologiche 48. Pavenski K, Rebulla P, Duquesnoy R, et al: International Collaboration for Guideline
Maligne dell’Adulto. N Engl J Med 337:1870, 1997. Development, Implementation, and Evaluation for Transfusion Therapies (ICTMG)
17. Wandt H, Frank M, Ehninger G, et al: Safety and cost effectiveness of a 10 × 10(9)/L Collaborators: Efficacy of HLA-matched platelet transfusions for patients with hypo-
rigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L proliferative thrombocytopenia: A systematic review. Transfusion 53:2230, 2013.
trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. 49. Vassallo RR, Fung M, Rebulla P, et al for the International Collaboration for Guideline
Blood 91:3601, 1998. Development, Implementation and Evaluation for Transfusion Therapies: Utility of
18. Heckman KD, Weiner GJ, Davis CS, et al: Randomized study of prophylactic plate- cross-matched platelet transfusions in patients with hypoproliferative thrombocytope-
let transfusion threshold during induction therapy for adult acute leukemia: 10,000/ nia: A systematic review. Transfusion 54:1180, 2014.
microL versus 20,000/microL. J Clin Oncol 15:1143, 1997. 50. Aster RH: Pooling of platelets in the spleen: Role in the pathogenesis of “hypersplenic”
19. Diedrich B, Remberger M, Shanwell A, et al: A prospective randomized trial of a pro- thrombocytopenia. J Clin Invest 45:645, 1966.
phylactic platelet transfusion trigger of 10 × 10(9) per L versus 30 × 10(9) per L in allo- 51. Ballem PJ, Segal GM, Stratton JR: Mechanisms of thrombocytopenia in chronic auto-
geneic hematopoietic progenitor cell transplant recipients. Transfusion 45:1064, 2005. immune thrombocytopenic purpura. Evidence of both impaired platelet production
20. Slichter SJ, Le Blanc R, Jones MK, et al: Quantitative analysis of bleeding risk in cancer and increased platelet clearance. J Clin Invest 80:33, 1987.
patients prophylactically transfused at platelet counts of 5,000 10,000 or 20,000 plts/μl. 52. Goel R, Ness PM, Takemoto, et al: Platelet transfusions in platelet consumptive disorders
Blood 94:376a, 1999. are associated with arterial thrombosis and in-hospital mortality. Blood 125:1470, 2015.
21. Kaufman RM, Djulbegovic B, Gernsheimer T, et al: Platelet Transfusion: A clinical 53. Jain S, Gernsheimer T, Slichter S: A retrospective analysis of epsilon-amino-caproic
practice guideline from the AABB. Ann Intern Med 162:205, 2015. acid therapy in hypoproliferative thrombocytopenia. European Hematology Association
22. Haas FJ, van Rhenen DJ, de Vries RR, et al; National Users’ Board Sanquin Blood Sup- Annual Meetings, P1040, unpublished 2013.
ply: Blood Transfusion Guideline. 2011. http://www.sanquin.nl/repository/documen- 54. Slichter SJ, Harker LA: Preparation and storage of platelet concentrates. I. Factors influ-
ten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf. encing the harvest of viable platelets from whole blood. Br J Haematol 34:395, 1976.
23. Norol F, Kuentz M, Cordonnier C, et al: Influence of clinical status on the efficacy of 55. Pietersz RN, Loos JA, Reesink HW: Platelet concentrates stored in plasma for 72 hours
stored platelet transfusion. Rev Fr Transfus Hemobiol 36:427, 1993. at 22°C prepared from buffy coats of citrate-phosphate-dextrose blood collected in a
24. Wandt H, Schaefer-Eckart K, Wendelin K, et al: Therapeutic platelet transfusion ver- quadruple-bag saline-adenine-glucose-mannitol system. Vox Sang 49:81, 1985.
sus routine prophylactic transfusion in patients with haematological malignancies: An 56. Keegan T, Heaton A, Holme S, et al: Paired comparison of platelet concentrates pre-
111
open-label, multicentre, randomised study. Lancet 380:1309, 2012. pared from platelet-rich plasma and buffy coats using a new technique with In and
25. Riley W, Smalley B, Pulkrabek S, et al: Using lean techniques to define the platelet trans- 51 Cr. Transfusion 32:113, 1992.
fusion process and cost effectiveness to evaluate platelet dose transfusion strategies. 57. Cardigan R, Williamson LM: The quality of platelets after storage for 7 days. Transfus
Transfusion 52:1957, 2012. Med 13:173, 2003.
26. Giagounidis A, Mufti GJ, Fenaux P, et al: Results of a randomized, double-blind study of 58. Dumont LJ, Dumont DF, Unger ZM, et al for the BEST Collaborative: A randomized
romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic controlled trial comparing autologous radiolabeled in vivo platelet recoveries and sur-
syndrome and thrombocytopenia. Cancer 120:1838, 2014. vivals of 7-day stored platelet-rich plasma and buffy coat platelets from the same sub-
27. Kumar A, Mhaskar R, Grossman BJ, et al: Platelet transfusion: A systematic review of jects. Transfusion 51:1241, 2011.
the clinical evidence. Transfusion 55:1116, 2015. 59. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted
28. Zeidler K, Arn K, Senn O, et al:. Optimal preprocedural platelet transfusion threshold viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 334:1685,
for central venous catheter insertions in patients with thrombocytopenia. Transfusion 1996.
51:2269, 2011. 60. Ness P, Braine H, King K, et al: Single-donor platelets reduce the risk of septic platelet
29. Haas B, Chittams JL, Trerotola S: Large-bore tunneled central venous catheter insertion transfusion reactions. Transfusion 41:857, 2001.
in patients with coagulopathy. J Vasc Interv Radiol 21:212, 2010. 61. Fridey JL, editor: Standards for Blood Banks and Transfusion Services, 22nd ed, p 13.
30. Howard SC, Gajjar A, Ribeiro, et al: Safety of lumbar puncture for children with acute American Association of Blood Banks, Bethesda, MD, 2003.
lymphoblastic leukemia and thrombocytopenia. JAMA 284:2222, 2000. 62. Chambers LA, Herman JH: Considerations in the selection of a platelet component:
31. Vavricka SR, Walter RB, Irani S, et al: Safety of lumbar puncture for adults with acute Apheresis versus whole blood-derived. Transfus Med Rev 13:311, 1999.
leukemia and restrictive prophylactic platelet transfusion. Ann Hematol 82:570, 2003. 63. Heddle NM, Cook RJ, Blajchman MA, et al: Assessing the effectiveness of whole
32. Bishop JF, Schiffer CA, Aisner J, et al: Surgery in acute leukemia: A review of 167 oper- blood-derived platelets stored as a pool: A randomized block noninferiority trial.
ations in thrombocytopenic patients. Am J Hematol 26:147, 1987. Transfusion 45:896, 2005.

Kaushansky_chapter 139_p2381-2392.indd 2390 9/18/15 2:23 PM